Transcranial magnetic stimulation

Last updated
Transcranial magnetic stimulation
Transcranial magnetic stimulation.jpg
Transcranial magnetic stimulation
(schematic diagram)
Specialty Psychiatry, neurology
MeSH D050781

Transcranial magnetic stimulation (TMS) is a noninvasive neurotherapy, a form of brain stimulation in which a changing magnetic field is used to induce an electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil connected to the scalp. The stimulator generates a changing electric current within the coil which creates a varying magnetic field, inducing a current within a region in the brain itself. [1] : 3  [2]

Contents

TMS has shown diagnostic and therapeutic potential in the central nervous system with a wide variety of disease states in neurology and mental health, but has not demonstrated clinical worth for treatment of any other condition. [3]

Adverse effects of TMS appear rare and include fainting and seizure. [4]

Medical uses

A magnetic coil is positioned on the patient's head. Neuro-ms.png
A magnetic coil is positioned on the patient's head.

TMS does not require surgery or electrode implantation.

Its use can be diagnostic and/or therapeutic. Effects vary based on frequency and intensity of the magnetic pulses as well as the length of treatment, which dictates the total number of pulses given. [6] TMS treatments are approved by the FDA in the US and by NICE in the UK for the treatment of depression and are provided by private clinics and some VA medical centers. TMS stimulates cortical tissue without the pain sensations produced in transcranial electrical stimulation. [7]

Diagnosis

TMS can be used clinically to measure activity and function of specific brain circuits in humans, most commonly with single or paired magnetic pulses. [8] The most widely accepted use is in measuring the connection between the primary motor cortex of the central nervous system and the peripheral nervous system to evaluate damage related to past or progressive neurologic insult. [8] [9] [10] [11] TMS has utility as a diagnostic instrument for myelopathy, amyotrophic lateral sclerosis, and multiple sclerosis. [12]

Treatment

There is some evidence that TMS may have applications for a number of conditions including depression, fibromyalgia and neuropathic pain, and TMS treatment is covered by most private insurance plans as well as by traditional Medicare, but for no condition does the evidence rise to the level of showing clinical relevance. [3]

Adverse effects

TMS is generally advertised as a safe alternative to medications such as SSRI's. The greatest immediate risk from TMS is fainting, though this is uncommon. Seizures have been reported, but are rare. [4] [13] [14]

Risks are higher for therapeutic repetitive TMS (rTMS) than for single or paired diagnostic TMS. [15] Adverse effects generally increase with higher frequency stimulation. [4]

Procedure

During the procedure, a magnetic coil is positioned at the head of the person receiving the treatment using anatomical landmarks on the skull, in particular the inion and nasion. [5] The coil is then connected to a pulse generator, or stimulator, that delivers electric current to the coil. [2]

Physics

TMS focal field.png
TMS - butterfly coils TMS Butterfly Coil HEAD.png
TMS – butterfly coils

TMS uses electromagnetic induction to generate an electric current across the scalp and skull. [16] [17] A plastic-enclosed coil of wire is held next to the skull and when activated, produces a varying magnetic field oriented orthogonally to the plane of the coil. The changing magnetic field then induces an electric current in the brain that activates nearby nerve cells in a manner similar to a current applied superficially at the cortical surface. [18]

The magnetic field is about the same strength as magnetic resonance imaging (MRI), and the pulse generally reaches no more than 5 centimeters into the brain unless using a modified coil and technique for deeper stimulation. [17]

Transcranial magnetic stimulation is achieved by quickly discharging current from a large capacitor into a coil to produce pulsed magnetic fields between 2 and 3 teslas in strength. [19] Directing the magnetic field pulse at a targeted area in the brain causes a localized electrical current which can then either depolarize or hyperpolarize neurons at that site. The induced electric field inside the brain tissue causes a change in transmembrane potentials resulting in depolarization or hyperpolarization of neurons, causing them to be more or less excitable, respectively. [19]

TMS usually stimulates to a depth from 2 to 4 cm below the surface, depending on the coil and intensity used. Consequently, only superficial brain areas can be affected. [20] Deep TMS can reach up to 6 cm into the brain to stimulate deeper layers of the motor cortex, such as that which controls leg motion. The path of this current can be difficult to model because the brain is irregularly shaped with variable internal density and water content, leading to a nonuniform magnetic field strength and conduction throughout its tissues. [21]

Frequency and duration

The effects of TMS can be divided based on frequency, duration and intensity (amplitude) of stimulation: [22]

Coil types

Most devices use a coil shaped like a figure-eight to deliver a shallow magnetic field that affects more superficial neurons in the brain. [27] Differences in magnetic coil design are considered when comparing results, with important elements including the type of material, geometry and specific characteristics of the associated magnetic pulse.

The core material may be either a magnetically inert substrate ('air core'), or a solid, ferromagnetically active material ('solid core'). Solid cores result in more efficient transfer of electrical energy to a magnetic field and reduce energy loss to heat, and so can be operated with the higher volume of therapy protocols without interruption due to overheating. Varying the geometric shape of the coil itself can cause variations in focality, shape, and depth of penetration. Differences in coil material and its power supply also affect magnetic pulse width and duration. [28]

A number of different types of coils exist, each of which produce different magnetic fields. The round coil is the original used in TMS. Later, the figure-eight (butterfly) coil was developed to provide a more focal pattern of activation in the brain, and the four-leaf coil for focal stimulation of peripheral nerves. The double-cone coil conforms more to the shape of the head. [29] The Hesed (H-core), circular crown and double cone coils allow more widespread activation and a deeper magnetic penetration. They are supposed to impact deeper areas in the motor cortex and cerebellum controlling the legs and pelvic floor, for example, though the increased depth comes at the cost of a less focused magnetic pulse. [4]

Research directions

For Parkinson's disease, early results suggest that low frequency stimulation may have an effect on medication associated dyskinesia, and that high frequency stimulation improves motor function. [30] [31]

History

Luigi Galvani (1737–1798) undertook research on the effects of electricity on the body in the late-eighteenth century and laid the foundations for the field of electrophysiology. [32] In the 1830s Michael Faraday (1791–1867) discovered that an electrical current had a corresponding magnetic field, and that changing one could induce its counterpart. [33]

Work to directly stimulate the human brain with electricity started in the late 1800s, and by the 1930s the Italian physicians Cerletti and Bini had developed electroconvulsive therapy (ECT). [32] ECT became widely used to treat mental illness, and ultimately overused, as it began to be seen as a panacea. This led to a backlash in the 1970s. [32]

In 1980 Merton and Morton successfully used transcranial electrical stimulation (TES) to stimulate the motor cortex. However, this process was very uncomfortable, and subsequently Anthony T. Barker began to search for an alternative to TES. [34] He began exploring the use of magnetic fields to alter electrical signaling within the brain, and the first stable TMS devices were developed in 1985. [32] [33] They were originally intended as diagnostic and research devices, with evaluation of their therapeutic potential being a later development. [32] [33] The United States' FDA first approved TMS devices in October 2008. [32]

Regulatory status

Speech mapping prior to neurosurgery

Nexstim obtained United States Federal Food, Drug, and Cosmetic Act§Section 510(k) clearance for the assessment of the primary motor cortex for pre-procedural planning in December 2009 [35] and for neurosurgical planning in June 2011. [36]

Depression

TMS is approved as a Class II medical device under the "de novo pathway". [37] [38]

Obsessive–compulsive disorder (OCD)

In August 2018, the US Food and Drug Administration (US FDA) authorized the use of TMS developed by the Israeli company Brainsway in the treatment of obsessive–compulsive disorder (OCD). [39]

In 2020, US FDA authorized the use of TMS developed by the U.S. company MagVenture Inc. in the treatment of OCD. [40]

In 2023, US FDA authorized the use of TMS developed by the U.S. company Neuronetics Inc. in the treatment of OCD. [41]

Other neurological areas

In the European Economic Area, various versions of deep TMS H-coils have CE marking for Alzheimer's disease, [42] autism, [42] bipolar disorder, [43] epilepsy, [44] chronic pain, [43] major depressive disorder, [43] Parkinson's disease, [45] [46] post-traumatic stress disorder (PTSD), [43] [47] schizophrenia (negative symptoms) [43] and to aid smoking cessation. [42] One review found tentative benefit for cognitive enhancement in healthy people. [48]

Coverage by health services and insurers

United Kingdom

The United Kingdom's National Institute for Health and Care Excellence (NICE) issues guidance to the National Health Service (NHS) in England, Wales, Scotland and Northern Ireland (UK). NICE guidance does not cover whether or not the NHS should fund a procedure. Local NHS bodies (primary care trusts and hospital trusts) make decisions about funding after considering the clinical effectiveness of the procedure and whether the procedure represents value for money for the NHS. [49]

NICE evaluated TMS for severe depression in 2007, finding that TMS was safe, but with insufficient evidence for its efficacy. [50] Guidance was updated and replaced in 2015, concluding that evidence for short‑term efficacy of repetitive transcranial magnetic stimulation (rTMS) for depression was adequate, although the clinical response is variable, and ruling that rTMS for depression may be used with arrangements for clinical governance and audit. [51]

In January 2014, NICE reported the results of an evaluation of TMS for treating and preventing migraine (IPG 477). NICE found that short-term TMS is safe but there is insufficient evidence to evaluate safety for long-term and frequent uses. It found that evidence on the efficacy of TMS for the treatment of migraine is limited in quantity, that evidence for the prevention of migraine is limited in both quality and quantity. [52]

As of 2025 use of rTMS in the UK was reported to have remained limited due to the cost of equipment and establishing treatment centres. Camilla Nord, head of the Mental Health Neuroscience Lab at the University of Cambridge said "The NHS has unfortunately been far behind the US and Canada on rTMS, which is at least as effective as antidepressants, if not more". [53]

United States

Commercial health insurance

In 2013, several commercial health insurance plans in the United States, including Anthem, Health Net, Kaiser Permanente, and Blue Cross Blue Shield of Nebraska and of Rhode Island, covered TMS for the treatment of depression for the first time. [54] [55] [56] [57] In contrast, UnitedHealthcare issued a medical policy for TMS in 2013 that stated there is insufficient evidence that the procedure is beneficial for health outcomes in patients with depression. UnitedHealthcare noted that methodological concerns raised about the scientific evidence studying TMS for depression include small sample size, lack of a validated sham comparison in randomized controlled studies, and variable uses of outcome measures. [58] Other commercial insurance plans whose 2013 medical coverage policies stated that the role of TMS in the treatment of depression and other disorders had not been clearly established or remained investigational included Aetna, Cigna and Regence. [59] [60] [61]

Medicare

Policies for Medicare coverage vary among local jurisdictions within the Medicare system, [62] and Medicare coverage for TMS has varied among jurisdictions and with time. For example:

  • In early 2012 in New England, Medicare covered TMS for the first time in the United States. [63] [64] [65] [66] However, that jurisdiction later decided to end coverage after October, 2013. [67]
  • In August 2012, the jurisdiction covering Arkansas, Louisiana, Mississippi, Colorado, Texas, Oklahoma, and New Mexico determined that there was insufficient evidence to cover the treatment, [68] but the same jurisdiction subsequently determined that Medicare would cover TMS for the treatment of depression after December 2013. [69]

Limitations

There are serious concerns about stimulating brain tissue using non-invasive magnetic field methods such as uncertainty in the dose and localisation of the stimulation effect. [70] [71] [72] [73]

See also

Related Research Articles

<span class="mw-page-title-main">Phosphene</span> Visual illusion

A phosphene is the phenomenon of seeing light without light entering the eye. The word phosphene comes from the Greek words phos (light) and phainein. Phosphenes that are induced by movement or sound may be associated with optic neuritis.

Neurotechnology encompasses any method or electronic device which interfaces with the nervous system to monitor or modulate neural activity.

Neurohacking is a subclass of biohacking, focused specifically on the brain. Neurohackers seek to better themselves or others by “hacking the brain” to improve reflexes, learn faster, or treat psychological disorders. The modern neurohacking movement has been around since the 1980s. However, herbal supplements have been used to increase brain function for hundreds of years. After a brief period marked by a lack of research in the area, neurohacking started regaining interest in the early 2000s. Currently, most neurohacking is performed via do-it-yourself (DIY) methods by in-home users.

Bioelectromagnetics, also known as bioelectromagnetism, is the study of the interaction between electromagnetic fields and biological entities. Areas of study include electromagnetic fields produced by living cells, tissues or organisms, the effects of man-made sources of electromagnetic fields like mobile phones, and the application of electromagnetic radiation toward therapies for the treatment of various conditions.

Treatment-resistant depression (TRD) is major depressive disorder in which an affected person does not respond adequately to at least two different antidepressant medications at an adequate dose and for an adequate duration. Inadequate response has most commonly been defined as less than 25% reduction in depressive symptoms following treatment with an antidepressant. Many clinicians and researchers question the construct validity and clinical utility of treatment-resistant depression as currently conceptualized.

<span class="mw-page-title-main">Transcranial direct-current stimulation</span> Technique of brain electric stimulation therapy

Transcranial direct current stimulation (tDCS) is a form of neuromodulation that uses constant, low direct current delivered via electrodes on the head. This type of neurotherapy was originally developed to help patients with brain injuries or neuropsychiatric conditions such as major depressive disorder. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way, as well as transcranial magnetic stimulation.

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. 

Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices.

Magnetic seizure therapy (MST) is a proposed form of electrotherapy and electrical brain stimulation. It is currently being investigated for the treatment of major depressive disorder, treatment-resistant depression (TRD), bipolar depression, schizophrenia and obsessive-compulsive disorder. MST is stated to work by inducing seizures via magnetic fields, in contrast to ECT which does so using alternating electric currents. Additionally, MST works in a more concentrated fashion than ECT, thus able to create a seizure with less of a total electric charge. In contrast to (r)TMS, the stimulation rates are higher resulting in more energy transfer. Currently it is thought that MST works in patients with major depressive disorder by activating the connection between the subgenual anterior cingulate cortex and the parietal cortex.

Neurostimulation is the purposeful modulation of the nervous system's activity using invasive or non-invasive means. Neurostimulation usually refers to the electromagnetic approaches to neuromodulation.

Cortical stimulation mapping (CSM) is a type of electrocorticography that involves a physically invasive procedure and aims to localize the function of specific brain regions through direct electrical stimulation of the cerebral cortex. It remains one of the earliest methods of analyzing the brain and has allowed researchers to study the relationship between cortical structure and systemic function. Cortical stimulation mapping is used for a number of clinical and therapeutic applications, and remains the preferred method for the pre-surgical mapping of the motor cortex and language areas to prevent unnecessary functional damage. There are also some clinical applications for cortical stimulation mapping, such as the treatment of epilepsy.

<span class="mw-page-title-main">Brainsway</span>

BrainsWay Ltd. is an international company that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a non-invasive treatment for depression, OCD, and smoking addiction. The company was founded in 2003 and has offices in the US and Jerusalem.

Neuromodulation is "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". It is carried out to normalize – or modulate – nervous tissue function. Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli such as a magnetic field (rTMS), an electric current, or a drug instilled directly in the subdural space. Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), and by 2014, these had been at minimum demonstrated in mammalian models, or first-in-human data had been acquired. The most clinical experience has been with electrical stimulation.

Transcranial random noise stimulation (tRNS) is a non-invasive brain stimulation technique and a form of transcranial electrical stimulation (tES). Terney et al from Göttingen University was the first group to apply tRNS in humans in 2008. They showed that by using an alternate current along with random amplitude and frequency in healthy subjects, the motor cortex excitability increased for up to 60 minutes after 10 minutes of stimulation. The study included all the frequencies up to half of the sampling rate i.e. 640 Hz, however the positive effect was limited only to higher frequencies. Although tRNS has shown positive effects in various studies the optimal parameters, as well as the potential clinical effects of this technique, remain unclear.

Gait variability seen in Parkinson's Disorders arise due to cortical changes induced by pathophysiology of the disease process. Gait rehabilitation is focused to harness the adapted connections involved actively to control these variations during the disease progression. Gait variabilities seen are attributed to the defective inputs from the Basal Ganglia. However, there is altered activation of other cortical areas that support the deficient control to bring about a movement and maintain some functional mobility.

<span class="mw-page-title-main">Abraham Zangen</span> Israeli researcher

Abraham Zangen is an Israeli professor of neuroscience, head of the brain stimulation and behavior lab and chair of the psychobiology brain program at Ben-Gurion University of the Negev (BGU).

Non-invasive cerebellar stimulation is the application of non-invasive neurostimulation techniques on the cerebellum to modify its electrical activity. Techniques such as transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) can be used. The cerebellum is a high potential target for neuromodulation of neurological and psychiatric disorders due to the high density of neurons in its superficial layer, its electrical properties, and its participation in numerous closed-loop circuits involved in motor, cognitive, and emotional functions.

Todd M. Hutton is an American psychiatrist specializing in transcranial magnetic stimulation (TMS). He is Associate Clinical Professor of Psychiatry at the Keck School of Medicine of the University of Southern California. Hutton is also currently President of the Clinical TMS Society, as well as the founder and medical director of the Southern California TMS Center.

<span class="mw-page-title-main">Friedhelm Hummel</span> German neuroscientist and neurologist

Friedhelm Christoph Hummel is a German neuroscientist and neurologist. A full professor at École Polytechnique Fédérale de Lausanne, he is the Defitech Chair of Clinical Neuroengineering, and the head of the Hummel Laboratory at EPFL's School of Life Sciences. He also is an associate professor of clinical neuroscience at the University of Geneva.

Raffaele Nardone is an Italian medical doctor, neurologist, and neuroscientist, known for his contributions in the field of clinical neurophysiology. He is the chair of the Department of Neurology at the Franz Tappeiner Hospital in Merano, Italy.

References

  1. ↑ "Transcranial magnetic stimulation for treating and preventing migraine". National Institute for Health and Care Excellence. January 2014.
  2. 1 2 Miller, Michael Craig (July 26, 2012). "Magnetic stimulation: a new approach to treating depression?". Harvard Health Publishing.
  3. 1 2 Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, et al. (February 2020). "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)". Clin Neurophysiol. 131 (2): 474–528. doi:10.1016/j.clinph.2019.11.002. hdl: 10362/147799 . PMID   31901449. The present work only provides arguments to be confident that some rTMS protocols do something that is different from a placebo in some indications, but not that the results obtained are clinically relevant
  4. 1 2 3 4 Rossi; et al. (January 2021). "Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines". Clinical Neurophysiology. 132 (1): 269–306. doi:10.1016/j.clinph.2020.10.003. PMC   9094636 . PMID   33243615. S2CID   225049093.
  5. 1 2 Nauczyciel C, Hellier P, Morandi X, Blestel S, Drapier D, Ferre JC, et al. (April 2011). "Assessment of standard coil positioning in transcranial magnetic stimulation in depression". Psychiatry Research. 186 (2–3): 232–8. doi:10.1016/j.psychres.2010.06.012. PMID   20692709. S2CID   25100990.
  6. ↑ Klomjai, Wanalee; Katz, Rose; Lackmy-Vallée, Alexandra (2015-09-01). "Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS)". Annals of Physical and Rehabilitation Medicine. 58 (4): 208–213. doi: 10.1016/j.rehab.2015.05.005 . ISSN   1877-0657. PMID   26319963.
  7. ↑ Lefaucher, Jean-Pascal (2019). "37. Transcranial magnetic stimulation". In Levin, Kerry H.; Chauvel, Patrick (eds.). Clinical Neurophysiology: Basis and Technical Aspects. Handbook of Clinical Neurology. Vol. 160. Elsevier. pp. 559–580. doi:10.1016/B978-0-444-64032-1.00037-0. ISBN   978-0-444-64032-1.
  8. 1 2 Groppa S, Oliviero A, Eisen A, Quartarone A, Cohen LG, Mall V, et al. (May 2012). "A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee". Clinical Neurophysiology. 123 (5): 858–882. doi:10.1016/j.clinph.2012.01.010. PMC   4890546 . PMID   22349304.
  9. ↑ Rossini PM, Rossi S (February 2007). "Transcranial magnetic stimulation: diagnostic, therapeutic, and research potential". Neurology. 68 (7): 484–8. doi:10.1212/01.wnl.0000250268.13789.b2. PMID   17296913. S2CID   19629888.
  10. ↑ Dimyan MA, Cohen LG (February 2010). "Contribution of transcranial magnetic stimulation to the understanding of functional recovery mechanisms after stroke". Neurorehabilitation and Neural Repair. 24 (2): 125–135. doi:10.1177/1545968309345270. PMC   2945387 . PMID   19767591.
  11. ↑ Nowak DA, Bösl K, Podubeckà J, Carey JR (2010). "Noninvasive brain stimulation and motor recovery after stroke". Restorative Neurology and Neuroscience. 28 (4): 531–544. doi:10.3233/RNN-2010-0552. PMID   20714076.
  12. ↑ Chen R, Cros D, Curra A, Di Lazzaro V, Lefaucheur JP, Magistris MR, Mills K, Rösler KM, Triggs WJ, Ugawa Y, Ziemann U (March 2008). "The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee". Clin Neurophysiol. 119 (3): 504–532. doi:10.1016/j.clinph.2007.10.014. PMID   18063409.
  13. ↑ Dobek CE, Blumberger DM, Downar J, Daskalakis ZJ, Vila-Rodriguez F (2015). "Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion". Neuropsychiatric Disease and Treatment. 11: 2975–87. doi: 10.2147/NDT.S91126 . PMC   4670017 . PMID   26664122.
  14. ↑ Fitzgerald PB, Daskalakis ZJ (2013). "7. rTMS-Associated Adverse Events". Repetitive Transcranial Magnetic Stimulation for Depressive Disorders. Springer. pp. 81–90. doi:10.1007/978-3-642-36467-9_7. ISBN   978-3-642-36466-2.
  15. ↑ van den Noort M, Lim S, Bosch P (December 2014). "Recognizing the risks of brain stimulation". Science. 346 (6215): 1307. doi:10.1126/science.346.6215.1307-a. hdl: 2066/133976 . PMID   25504707.
  16. ↑ Cavaleri R, Schabrun SM, Chipchase LS (March 2017). "The number of stimuli required to reliably assess corticomotor excitability and primary motor cortical representations using transcranial magnetic stimulation (TMS): a systematic review and meta-analysis". Systematic Reviews. 6 (1): 48. doi: 10.1186/s13643-017-0440-8 . PMC   5340029 . PMID   28264713.
  17. 1 2 "Brain Stimulation Therapies". NIMH.
  18. ↑ Cacioppo JT, Tassinary LG, Berntson GG, eds. (2007). Handbook of psychophysiology (3rd ed.). Cambridge University Press. p. 121. doi:10.1017/CBO9780511546396. ISBN   978-0-521-84471-0.
  19. 1 2 Walsh, V.; Pascual-Leone, A. (2003). Transcranial Magnetic Stimulation: A Neurochronometrics of Mind. Cambridge, MA: MIT Press. doi:10.7551/mitpress/6896.001.0001. ISBN   978-0-262-28573-5. OCLC   53889320.
  20. ↑ Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipović SR, Hummel FC, Jääskeläinen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schönfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L (November 2014). "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)". Clin Neurophysiol. 125 (11): 2150–2206. doi:10.1016/j.clinph.2014.05.021. PMID   25034472.
  21. ↑ See:
    1. Zangen A, Roth Y, Voller B, Hallett M (April 2005). "Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil". Clinical Neurophysiology. 116 (4): 775–9. doi:10.1016/j.clinph.2004.11.008. PMID   15792886. S2CID   25101101.
    2. Huang YZ, Sommer M, Thickbroom G, Hamada M, Pascual-Leonne A, Paulus W, et al. (January 2009). "Consensus: New methodologies for brain stimulation". Brain Stimulation. 2 (1): 2–13. doi:10.1016/j.brs.2008.09.007. PMC   5507351 . PMID   20633398.
  22. ↑ Rubens MT, Zanto TP (March 2012). "Parameterization of transcranial magnetic stimulation". Journal of Neurophysiology. 107 (5): 1257–9. doi:10.1152/jn.00716.2011. PMC   3311692 . PMID   22072509.
  23. ↑ Pascual-Leone A, Davey N, Rothwell J, Wassermann EM, Puri BK (2002). Handbook of Transcranial Magnetic Stimulation. London: Edward Arnold. ISBN   978-0-340-72009-7. OCLC   47824021.
  24. ↑ Cusin C, Dougherty DD (August 2012). "Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS". Biology of Mood & Anxiety Disorders. 2 (1): 14. doi: 10.1186/2045-5380-2-14 . PMC   3514332 . PMID   22901565.
  25. ↑ Fitzgerald PB, Fountain S, Daskalakis ZJ (December 2006). "A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition". Clinical Neurophysiology. 117 (12): 2584–96. doi:10.1016/j.clinph.2006.06.712. PMID   16890483. S2CID   31458874.
  26. ↑ Baur D, Galevska D, Hussain S, Cohen LG, Ziemann U, Zrenner C (2020). "Induction of LTD-like corticospinal plasticity by low-frequency rTMS depends on pre-stimulus phase of sensorimotor μ-rhythm". Brain Stimul. 13 (6): 1580–7. doi:10.1016/j.brs.2020.09.005. PMC   7710977 . PMID   32949780.
  27. ↑ Bersani, F.S.; Minichino, A.; Enticott, P.G.; Mazzarini, L.; Khan, N.; Antonacci, G.; Raccah, R.N.; Salviati, M.; Delle Chiaie, R.; Bersani, G.; Fitzgerald, P.B.; Biondi, M. (January 2013). "Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: A comprehensive review". European Psychiatry. 28 (1): 30–39. doi:10.1016/j.eurpsy.2012.02.006. PMID   22559998. S2CID   29053871.
  28. ↑ Riehl M (2008). "TMS Stimulator Design". In Wassermann EM, Epstein CM, Ziemann U, Walsh V, Paus T, Lisanby SH (eds.). Oxford Handbook of Transcranial Stimulation. Oxford: Oxford University Press. pp. 13–23, 25–32. doi:10.1093/oxfordhb/9780198568926.013.0003. ISBN   978-0-19-856892-6.
  29. ↑ Roth BJ, Maccabee PJ, Eberle LP, Amassian VE, Hallett M, Cadwell J, et al. (February 1994). "In vitro evaluation of a 4-leaf coil design for magnetic stimulation of peripheral nerve". Electroencephalography and Clinical Neurophysiology. 93 (1): 68–74. doi:10.1016/0168-5597(94)90093-0. PMID   7511524.
  30. ↑ Machado S, Bittencourt J, Minc D, Portella CE, Velasques B, Cunha M, et al. (2008). "Therapeutic applications of repetitive transcranial magnetic stimulation in clinical neurorehabilitation". Functional Neurology. 23 (3): 113–122. PMID   19152730.
  31. ↑ Liu, Xuan; Li, Lei; Liu, Ye (2023-09-29). "Comparative motor effectiveness of non-invasive brain stimulation techniques in patients with Parkinson's disease: A network meta-analysis". Medicine. 102 (39): e34960. doi:10.1097/MD.0000000000034960. ISSN   1536-5964. PMC   10545289 . PMID   37773851.
  32. 1 2 3 4 5 6 Horvath JC, Perez JM, Forrow L, Fregni F, Pascual-Leone A (March 2011). "Transcranial magnetic stimulation: a historical evaluation and future prognosis of therapeutically relevant ethical concerns". Journal of Medical Ethics. 37 (3): 137–143. doi:10.1136/jme.2010.039966. JSTOR   23034661. PMID   21106996. S2CID   13262044.
  33. 1 2 3 Noohi S, Amirsalari S (2016). "History, Studies and Specific Uses of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treating Epilepsy". Iranian Journal of Child Neurology. 10 (1): 1–8. PMC   4815479 . PMID   27057180.
  34. ↑ Klomjai W, Katz R, Lackmy-Vallée A (September 2015). "Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS)". Annals of Physical and Rehabilitation Medicine. 58 (4): 208–213. doi: 10.1016/j.rehab.2015.05.005 . PMID   26319963.
  35. ↑ "FDA clears Nexstim´s Navigated Brain Stimulation for non-invasive cortical mapping prior to neurosurgery – Archive – Press Releases". nexstim.com.
  36. ↑ "Nexstim Announces FDA Clearance for NexSpeech® – Enabling Noninvasive Speech Mapping Prior to Neurosurgery". businesswire.com. 11 June 2012.
  37. ↑ Michael Drues, for Med Device Online. 5 February 2014 Secrets Of The De Novo Pathway, Part 1: Why Aren't More Device Makers Using It?
  38. ↑ Schwedt TJ, Vargas B (September 2015). "Neurostimulation for Treatment of Migraine and Cluster Headache". Pain Medicine. 16 (9): 1827–34. doi:10.1111/pme.12792. PMC   4572909 . PMID   26177612.
  39. ↑ "FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder". Food and Drug Administration . 2020-02-20.
  40. ↑ "MagVenture receives FDA clearance for OCD | Clinical TMS Society". www.clinicaltmssociety.org. Retrieved 2023-10-11.
  41. ↑ "FDA clears OCD motor threshold cap for transcranial magnetic stimulation system". www.healio.com. Retrieved 2023-10-11.
  42. 1 2 3 "Brainsway reports positive Deep TMS system trial data for OCD". Medical Device Network. Medicaldevice-network. September 6, 2013. Archived from the original on November 4, 2013. Retrieved December 16, 2013.
  43. 1 2 3 4 5 "Brainsway's Deep TMS EU Cleared for Neuropathic Chronic Pain". medGadget. July 3, 2012. Retrieved December 16, 2013.
  44. ↑ Gersner R, Oberman L, Sanchez MJ, Chiriboga N, Kaye HL, Pascual-Leone A, et al. (2016-01-01). "H-coil repetitive transcranial magnetic stimulation for treatment of temporal lobe epilepsy: A case report". Epilepsy & Behavior Case Reports. 5 (Supplement C): 52–56. doi:10.1016/j.ebcr.2016.03.001. PMC   4832041 . PMID   27114902.
  45. ↑ Chou YH, Hickey PT, Sundman M, Song AW, Chen NK (April 2015). "Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis". JAMA Neurology. 72 (4): 432–440. doi:10.1001/jamaneurol.2014.4380. PMC   4425190 . PMID   25686212.
  46. ↑ Torres F, Villalon E, Poblete P, Moraga-Amaro R, Linsambarth S, Riquelme R, et al. (2015-10-26). "Retrospective Evaluation of Deep Transcranial Magnetic Stimulation as Add-On Treatment for Parkinson's Disease". Frontiers in Neurology. 6: 210. doi: 10.3389/fneur.2015.00210 . PMC   4620693 . PMID   26579065.
  47. ↑ Petrosino, Nicholas J.; Cosmo, Camila; Berlow, Yosef A.; Zandvakili, Amin; van ’t Wout-Frank, Mascha; Philip, Noah S. (2021). "Transcranial magnetic stimulation for post-traumatic stress disorder". Therapeutic Advances in Psychopharmacology . 11. doi: 10.1177/20451253211049921 . PMC   8558793 . PMID   34733479.
  48. ↑ Luber B, Lisanby SH (January 2014). "Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS)". NeuroImage. 85 Pt 3 (3): 961–970. doi:10.1016/j.neuroimage.2013.06.007. PMC   4083569 . PMID   23770409.
  49. ↑ NICE About NICE: What we do
  50. ↑ "Transcranial magnetic stimulation for severe depression". London: National Institute for Health and Clinical Excellence. 2011-03-04. IPG242.
  51. ↑ "Repetitive transcranial magnetic stimulation for depression". National Institute for Health and Clinical Excellence. 16 December 2015. IPG542. Retrieved 11 January 2025.
  52. ↑ "Transcranial magnetic stimulation for treating and preventing migraine". London: National Institute for Health and Clinical Excellence. 23 January 2014. Retrieved 11 January 2025.
  53. ↑ Cox, David (11 January 2025). "Is a brain-stimulation headset the answer to depression?". the Guardian.
  54. ↑ "Medical Policy: Transcranial Magnetic Stimulation for Depression and Other Neuropsychiatric Disorders". Policy No. BEH.00002. Anthem, Inc. 2013-04-16. Archived from the original on 2013-07-29. Retrieved 2013-12-11.
  55. ↑ Health Net (March 2012). "National Medical Policy: Transcranial Magnetic Stimulation" (PDF). Policy Number NMP 508. Health Net. Archived from the original (PDF) on 2012-10-11. Retrieved 2012-09-05.
  56. ↑ "Medical Policy Manual" (PDF). Section IV.67. Blue Cross Blue Shield of Nebraska. 2011-05-18. Archived from the original (PDF) on 2012-10-28.
  57. ↑ "Medical Coverage Policy: Transcranial Magnetic Stimulation for Treatment of Depression and Other Psychiatric/Neurologic Disorders" (PDF). Blue Cross Blue Shield of Rhode Island. 2012-05-15. Archived from the original (PDF) on 2013-05-26. Retrieved 2012-09-05.
  58. ↑ UnitedHealthcare (2013-12-01). "Transcranial Magnetic Stimulation" (PDF). UnitedHealthCare. p. 2. Archived from the original (PDF) on 2013-05-20. Retrieved 2013-12-11.
  59. ↑ Aetna (2013-10-11). "Clinical Policy Bulletin: Transcranial Magnetic Stimulation and Cranial Electrical Stimulation". Number 0469. Aetna. Archived from the original on 2013-10-22. Retrieved 2013-12-11.
  60. ↑ Cigna (2013-01-15). "Cigna Medical Coverage Policy: Transcranial Magnetic Stimulation" (PDF). Coverage Policy Number 0383. Cigna. Archived from the original (PDF) on 2017-02-04. Retrieved 2013-12-11.
  61. ↑ Regence (2013-06-01). "Medical Policy: Transcranial Magnetic Stimulation as a Treatment of Depression and Other Disorders" (PDF). Policy No. 17. Regence. Archived from the original (PDF) on 2014-12-09. Retrieved 2013-12-11.
  62. ↑ "Medicare Administrative Contractors". Centers for Medicare and Medicaid Services. 2013-07-10. Archived from the original on 2014-02-14. Retrieved 2014-02-14.
  63. ↑ NHIC, Corp. (2013-10-24). "Local Coverage Determination (LCD) for Repetitive Transcranial Magnetic Stimulation (rTMS) (L32228)". Centers for Medicare and Medicaid Services. Archived from the original on 2014-02-17. Retrieved 2014-02-17.
  64. ↑ "Important Treatment Option for Depression Receives Medicare Coverage". Press Release. PBN.com: Providence Business News. 2012-03-30. Archived from the original on 2013-04-05. Retrieved 2012-10-11.
  65. ↑ The Institute for Clinical and Economic Review (June 2012). "Coverage Policy Analysis: Repetitive Transcranial Magnetic Stimulation (rTMS)" (PDF). The New England Comparative Effectiveness Public Advisory Council (CEPAC). Archived from the original (PDF) on 2013-12-13. Retrieved 2013-12-11.
  66. ↑ "Transcranial Magnetic Stimulation Cites Influence of New England Comparative Effectiveness Public Advisory Council (CEPAC)". Berlin, Vermont: Central Vermont Medical Center. 2012-02-06. Archived from the original on 2012-03-25. Retrieved 2012-10-12.
  67. ↑ National Government Services, Inc. (2013-10-25). "Local Coverage Determination (LCD): Transcranial Magnetic Stimulation (L32038)". Centers for Medicare and Medicaid Services . Retrieved 2014-02-17.
  68. ↑ Novitas Solutions, Inc. (2013-12-04). "LCD L32752 – Transcranial Magnetic Stimulation for Depression". Contractor's Determination Number L32752. Centers for Medicare and Medicaid Services . Retrieved 2014-02-17.
  69. ↑ Novitas Solutions, Inc. (2013-12-05). "LCD L33660 – Transcranial Magnetic Stimulation (TMS) for the Treatment of Depression". Contractor's Determination Number L33660. Centers for Medicare and Medicaid Services . Retrieved 2014-02-17.
  70. ↑ Benussi A, Pascual-Leone A, Borroni B (March 2020). "Non-Invasive Cerebellar Stimulation in Neurodegenerative Ataxia: A Literature Review". Int J Mol Sci. 21 (6): 1948. doi: 10.3390/ijms21061948 . PMC   7139863 . PMID   32178459.
  71. ↑ Grimaldi G, Argyropoulos GP, Boehringer A, Celnik P, Edwards MJ, Ferrucci R, Galea JM, Groiss SJ, Hiraoka K, Kassavetis P, Lesage E, Manto M, Miall RC, Priori A, Sadnicka A, Ugawa Y, Ziemann U (February 2014). "Non-invasive cerebellar stimulation—a consensus paper". Cerebellum. 13 (1): 121–38. doi:10.1007/s12311-013-0514-7. PMID   23943521.
  72. ↑ Siebner HR, Hartwigsen G, Kassuba T, Rothwell JC (October 2009). "How does transcranial magnetic stimulation modify neuronal activity in the brain? Implications for studies of cognition". Cortex. 45 (9): 1035–42. doi:10.1016/j.cortex.2009.02.007. PMC   2997692 . PMID   19371866.
  73. ↑ Sparing R, Mottaghy FM (April 2008). "Noninvasive brain stimulation with transcranial magnetic or direct current stimulation (TMS/tDCS)-From insights into human memory to therapy of its dysfunction". Methods. 44 (4): 329–37. doi:10.1016/j.ymeth.2007.02.001. PMID   18374276.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.